Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: GRYPHON BIO INC
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2022-09-26 to 2024-12-24
Current total value of award: $749437
Description: PER SECTION 711 OF THE 2019 NDAA, USAMRAA TRANSFERRED TO DHA 10/1/2022. EXTENDING PERIOD OF PERFORMANCE. FEASIBILITY STUDY OF A SINGLE PLATFORM SOLUTION FOR BLOOD TESTING OF TBI BIOMARKERS.